Activation of iCaspase-9 in neovessels inhibits oral tumor progression

Journal of Dental Research

Volumn 85, Issue 5, 2006, Pages 436-441

  Pinsky, M S ^a   Song, W ^a   Dong, Z ^a   Warner, K ^a   Zeitlin, B ^a   Karl, E ^a   Hall, D E ^b   Nor J E ^a  

^a UNIVERSITY OF MICHIGAN SCHOOL OF DENTISTRY   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Angiogenesis; Apoptosis; Bioluminescence; Neovascularization; Suicide gene

Indexed keywords

CASP9 PROTEIN, HUMAN; CASP9 PROTEIN, MOUSE; CASPASE; CASPASE 9; LUCIFERASE;

ANALYSIS OF VARIANCE; ANIMAL; ARTICLE; CANCER TRANSPLANTATION; CELL CULTURE; DRUG EFFECT; ENZYME ACTIVATION; ENZYMOLOGY; HUMAN; LUMINESCENCE; MOUSE; MOUSE MUTANT; MOUTH TUMOR; NEOVASCULARIZATION (PATHOLOGY); PHYSIOLOGY; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE; VASCULAR ENDOTHELIUM; VASCULARIZATION;

ANALYSIS OF VARIANCE; ANIMALS; CARCINOMA, SQUAMOUS CELL; CASPASE 9; CASPASES; CELL LINE, TUMOR; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; ENZYME ACTIVATION; HUMANS; LUCIFERASES; LUMINESCENT MEASUREMENTS; MICE; MICE, SCID; MOUTH NEOPLASMS; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC;

EID: 33744462599     PISSN: 00220345     EISSN: None     Source Type: Journal    
DOI: 10.1177/154405910608500508     Document Type: Article

References (26)

1. Ali M, Lemoine NR, Ring CJ (1994). The use of DNA viruses as vectors for gene therapy. Gene Ther 1:367-384.
2. Chen Z, Malhotra PS, Thomas GR, Ondrey FG, Duffey DC, Smith CW, et al. (1999). Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin Cancer Res 5:1369-1379.
3. Dienst A, Grunow A, Unruh M, Rabausch B, Nör JE, Fries JW, et al. (2005). Specific occlusion of murine and human tumor vasculature by VCAM-1-targeted recombinant fusion proteins. J Natl Cancer Inst 97:733-747.
4. Edinger M, Cao YA, Horning YS, Jenkins DE, Verneris MR, Bachmann MH, et al. (2002). Advancing animal models of neoplasia through in vivo bioluminescence imaging. Eur J Cancer 38:2128-2136.
5. Fan L, Freeman KW, Khan T, Pham E, Spencer DM (1999). Improved artificial death switches based on caspases and FADD. Hum Gene Ther 10:2273-2285.
6. Folkman J (1971). Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182-1186.
7. Folkman J (1995). Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1:27-31.
8. Heidenreich R, Kappel A, Breier G (2000). Tumor endothelium-specific transgene expression directed by vascular endothelial growth factor-2 (Flk-1) promoter/enhancer sequences. Cancer Res 60:6142-6147.
9. Hu Y, Benedict MA, Wu D, Inohara N, Nunez G (1998). Bcl-XL interacts with Apaf-1 and inhibits Apaf-1-dependent caspase-9 activation. Proc Natl Acad Sci USA 95:4386-4391.
10. Kerbel RS (2000). Tumor angiogenesis: past, present and the near future. Carcinogenesis 21:505-515.
11. Kerbel R, Folkman J (2002). Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2:727-739.
12. Li H, Zhu H, Xu CJ, Yuan J (1998). Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94:491-501.
13. MacCorkle RA, Freeman KW, Spencer DM (1998). Synthetic activation of caspases: artificial death switches. Proc Natl Acad Sci USA 95:3655-3660.
14. Nör JE, Christensen J, Mooney DJ, Polverini PJ (1999). Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am J Pathol 154:375-384.
15. Nör JE, Christensen J, Liu J, Peters M, Mooney DJ, Stricter RM, et al. (2001a). Up-regulation of Bcl-2 in microvascular endothelial cells enhances intratumoral angiogenesis and accelerates tumor growth. Cancer Res 661:2183-2188.
16. Nör JE, Peters MC, Christensen JB, Sutorik MM, Linn S, Khan MK, et al. (2001b). Engineering and characterization of functional human microvessels in immunodeficient mice. Lab Invest 81:453-463.
17. Nör JE, Hu Y, Song W, Spencer DM, Nuñez G (2002). Ablation of microvessels in vivo upon dimerization of iCaspase-9. Gene Ther 9:444-451.
18. Nunez G, Benedict MA, Hu Y, Inohara N (1998). Caspases: the proteases of the apoptotic pathway. Oncogene 17:3237-3245.
19. Patterson C, Perrella MA, Hsieh CM, Yoshizumi M, Lee ME, Haber E (1995). Cloning and functional analysis of the promoter for KDR/flk-1, a receptor for vascular endothelial growth factor. J Biol Chem 270:23111-23118.
20. Polverini PJ (1995). The pathophysiology of angiogenesis. Crit Rev Oral Biol Med 6:230-247.
21. Rehemtulla A, Stegman LD, Cardozo SJ, Gupta S, Hall DE, Contag CH, et al. (2000). Rapid and quantitative assessment of cancer treatment response using in vivo bioluminescence imaging. Neoplasia 2:491-495.
22. Rudin CM, Cohen EE, Papadimitrakopoulou VA, Silverman S Jr, Recant W, El-Naggar AK, et al. (2003). An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia. J Clin Oncol 21:4546-4552.
23. Shariat SF, Desai S, Song W, Khan T, Zhao J, Nguyen C, et al. (2001). Adenovirus-mediated transfer of inducible caspases: a novel "death switch" gene therapeutic approach to prostate cancer. Cancer Res 61:2562-2571.
24. Song W, Sun Q, Dong Z, Spencer DM, Nunez G, Nör JE (2005). Antiangiogenic gene therapy: disruption of neovascular networks mediated by inducible caspase-9 delivered with a transcriptionally targeted adenoviral vector. Gene Ther 12:320-329.
25. St George JA (2003). Gene therapy progress and prospects: adenoviral vectors. Gene Ther 10:1135-1141.
26. Timmins GS, Robb FJ, Wilmot CM, Jackson SK, Swartz HM (2001). Firefly flashing is controlled by gating oxygen to light-emitting cells. J Exp Biol 204:2795-2801.